Bristol-Myers Squibb's (BMY) Opdivo for Treatment of Esophageal Cancer Granted Orphan Drug Status by FDA

August 24, 2016 8:32 AM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Bristol-Myers Squibb's (NYSE: BMY) Opdivo for treatment of esophageal cancer was granted orphan drug status by the FDA. The generic name is nivolumab.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment